A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
LigaChem Biosciences, Inc.
Intensity Therapeutics, Inc.
Novartis
Novartis
H. Lee Moffitt Cancer Center and Research Institute